Zinc Supplementation

PreclinicalSmall molecule

KKasr El Aini Hospital

Zinc Supplementation is one of 22 small molecule programs targeting Allergy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

AllergyPreclinical

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Allergy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Claritin

PPerrigo Company

Approved

1 4

Flagyl

DDePuy Orthopaedics

Approved

1 5

Potassium Citrate

MMission Pharmacal

Approved

1 6

Levaquin

WWim Janssens

Approved

1 7

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 8

Allegra

CChattem

Approved

1 9

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 10

Lastacaft

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 2·NCT00138047·100 enrolled

Allergy1 trial

Impact of Zinc as a New Adjuvant Therapy for Cow Milk Protein Allergy in Children.

Enrolling by invitation·KKasr El Aini Hospital·N/A·NCT06673082·190 enrolled

Oral Lichen Planus1 trial

Effect of Oral Zinc Supplementation as an Adjuvant to Topical Corticosteroid in Oral Lichen Planus Patients

Unknown status·PPostgraduate Institute of Dental Sciences Rohtak·Phase 4·NCT04278599·42 enrolled

Children1 trial

Zinc Supplementation and Nutrition Education Among Children in the Rural Community

Completed·UUniversity of Douala·Phase 2/3·NCT04574544·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Zinc Supplementation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zinc Supplementation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zinc Supplementation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kasr El Aini Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKasr El Aini Hospital

Zinc Supplementation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

Allergy1 trial

Oral Lichen Planus1 trial

Children1 trial

References

Drug Info

Quick Facts

Related News